Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by SignalPoint Asset Management LLC

SignalPoint Asset Management LLC lifted its position in shares of Exact Sciences Co. (NASDAQ:EXASGet Rating) by 13.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,581 shares of the medical research company’s stock after purchasing an additional 790 shares during the quarter. SignalPoint Asset Management LLC’s holdings in Exact Sciences were worth $460,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FSB Premier Wealth Management Inc. acquired a new stake in Exact Sciences in the 4th quarter valued at $36,000. Masso Torrence Wealth Management Inc. acquired a new stake in Exact Sciences in the 4th quarter valued at $37,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Exact Sciences in the 4th quarter valued at $37,000. HM Payson & Co. grew its stake in Exact Sciences by 118.6% in the 4th quarter. HM Payson & Co. now owns 481 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 261 shares during the period. Finally, Capital Advisory Group Advisory Services LLC acquired a new stake in Exact Sciences in the 1st quarter valued at $37,000. Institutional investors and hedge funds own 94.45% of the company’s stock.

Insider Transactions at Exact Sciences

In other news, Director Katherine S. Zanotti sold 4,608 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the transaction, the director now directly owns 60,318 shares of the company’s stock, valued at $2,722,754.52. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Katherine S. Zanotti sold 1,086 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the transaction, the director now directly owns 60,318 shares of the company’s stock, valued at $2,420,561.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Katherine S. Zanotti sold 4,608 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the sale, the director now owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,701 shares of company stock valued at $251,872. 1.40% of the stock is currently owned by corporate insiders.

Exact Sciences Price Performance

NASDAQ EXAS traded down $2.32 during trading on Friday, hitting $47.05. The stock had a trading volume of 2,885,678 shares, compared to its average volume of 1,783,264. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.29 and a current ratio of 2.48. The firm has a 50 day moving average price of $44.58 and a 200 day moving average price of $59.00. Exact Sciences Co. has a twelve month low of $35.34 and a twelve month high of $108.99.

Wall Street Analyst Weigh In

EXAS has been the topic of several recent research reports. BTIG Research lowered their target price on shares of Exact Sciences from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday. Cowen lowered their target price on shares of Exact Sciences from $83.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday. Raymond James lowered their target price on shares of Exact Sciences from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday. Craig Hallum lowered their target price on shares of Exact Sciences from $81.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Piper Sandler started coverage on Exact Sciences in a report on Thursday, June 2nd. They set a “neutral” rating and a $50.00 price target on the stock. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $73.09.

Exact Sciences Company Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Read More

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.